 CAMBRIDGE, Mass., Oct. 7, 2021 PRNewswire -- Nuvalent, Inc., Nasdaq: NUVL, a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, provided new preclinical data on Thursday supporting advancement of its parallel lead programs in non-small cell lung cancer NSCLC. 